Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.56
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Data is available to registered users only
Buy
Sell